Millipore Sigma Vibrant Logo
Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

525330 PFKFB3 Inhibitor, 3PO - Calbiochem

525330
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

Empirical Formula
C₁₃H₁₀N₂O

Products

Numero di catalogoConfezionamento Qtà/conf
525330-25MG Bottiglia di vetro 25 mg
Description
OverviewA cell-permeable dipyridinyl-propenone compound that selectively blocks PFK-2 (6-phosphofructo-2-kinase) activity of PFKFB3 isozyme over PFK-1 (6-phosphofructo-1-kinase) in a mixed-mode manner. Rapidly decreases fructose-2,6-bisphosphate (F-2,6-P2) and 2-deoxyglucose uptake, and lactate secretion; efficiently arrests proliferation of transformed cells (IC50 ~ 1.4 µM in NHBE-ht/LT/ras) and suppresses tumor growth in several xenograft mouse models (70 mg/kg, i.p.). The cytostatic and cytotoxic effects of 3PO is shown to be highly sensitive to the intracellular levels of F-6-P (fructose-6-phosphate) and F-2,6-P2.
Catalogue Number525330
Brand Family Calbiochem®
Synonyms(2E)-3-Pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one, 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one, 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 Inhibitor, 3PO
References
ReferencesClem, B., et al. 2008. Mol. Cancer Ther. 7, 110.
Product Information
FormPale yellow solid
Hill FormulaC₁₃H₁₀N₂O
Chemical formulaC₁₃H₁₀N₂O
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥99% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numero di catalogo GTIN
525330-25MG 04055977270716

Documentation

PFKFB3 Inhibitor, 3PO - Calbiochem MSDS

Titolo

Scheda di sicurezza (MSDS) 

PFKFB3 Inhibitor, 3PO - Calbiochem Certificati d'Analisi

TitoloNumero di lotto
525330

Riferimenti bibliografici

Panoramica delle referenze
Clem, B., et al. 2008. Mol. Cancer Ther. 7, 110.
Scheda tecnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision27-July-2012 JSW
Synonyms(2E)-3-Pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one, 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one, 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 Inhibitor, 3PO
DescriptionA cell-permeable dipyridinyl-propenone compound that selectively blocks PFK-2 (6-phosphofructo-2-kinase) activity of PFKFB3 isozyme over PFK-1 (6-phosphofructo-1-kinase) in a mixed-mode manner. Rapidly decreases fructose-2,6-bisphosphate (F-2,6-P2) and 2-deoxyglucose uptake, and lactate secretion; efficiently arrests proliferation of transformed cells (IC50 ~ 1.4 µM in NHBE-ht/LT/ras) and suppresses tumor growth in several xenograft mouse models (70 mg/kg, i.p.). The cytostatic and cytotoxic effects of 3PO is shown to be highly sensitive to the intracellular levels of F-6-P (fructose-6-phosphate) and F-2,6-P2.
FormPale yellow solid
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₁₃H₁₀N₂O
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (50 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C.
Toxicity Standard Handling
ReferencesClem, B., et al. 2008. Mol. Cancer Ther. 7, 110.